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INTRODUCTION 
 
Glaucoma is a chronic optic neuropathy with a characteristic pattern of loss of optic nerve fibres and field of 
vision which can lead to visual impairment or even blindness in the most aggressive cases. Many subtypes of 
the disease are recognized, however primary open angle glaucoma (POAG) is the most common form 
worldwide. Yet POAG etiology is only partially understood and there is still uncertainty on the mechanism 
through which optic nerve fibres die. Intraocular pressure (IOP) is the only modifiable risk factor  and therefore 
the treatment of the disease focuses on its reduction by means of medications, laser treatments or surgeries.  
When it comes to surgery trabeculectomy is still the gold standard. This procedure was first described by 
Cairns1 in 1968 and then was subjected to many revisions to improve its safety and efficacy profile.2  
The suboptimal function or complete lack of drainage of a trabeculectomy bleb challenge the ophthalmologist 
to choose the most appropriate option in order to restore the adequate IOP control. In the early post-
trabeculectomy phase the cause of an increased IOP is usually a blockage at the level of the ostium (tissue, 
blood or vitreous), an excessive tightening of the scleral flap sutures or an increased resistance at the level of 
the conjunctiva due to a Tenon’s cyst formation or a scarred down bleb for a primary failure. On the other hand, 
in the late postoperative phase, even after years of successful drainage function, a trabeculectomy site may fail 
for an unfavorable deposition of fibrous tissue beneath the scleral flap or at the interface between the 
episclera and the conjunctival/Tenon’s capsule, compromising thus the filtration. This can happen both 
following a specific “trigger” for the extracellular matrix deposition, like an intervening cataract surgery, and 
also independently for nonspecific reasons. 
When the reason for a trabeculectomy failure is deemed to be an excess of fibrous tissue preventing the 
activity of the fistula, one has to opt for either a conservative management or a more aggressive interventional 
approach. In the decision making process many variables need to be born in mind: the mechanism of glaucoma, 
the technique employed for the original surgery, the state of the conjunctiva, the eventual comorbidities, the 
time to failure from the original surgery and the patient’s preference are some of them. 
The conservative management usually relies on the use of topical aqueous suppressants, such as carbonic 
anhydrase inhibitors, alpha-2 agonists and beta-blockers. However, in cases where the trabeculectomy is still at 
least partially functioning, some may argue that the reduction of flow might further deflate the bleb and 
promote its definite scarring down. In the early postoperative phase topical steroids have a widely accepted 
role in preventing excessive bleb scarring. However their effect on the trabeculectomy site at a later stage is 
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more controversial and the lack of a strong evidence on the matter, leave space for multiple views. While for 
some topical steroids are unlikely to affect the drainage, others are firm believers of a steroid response due to 
modifications on the trabecular meshwork or on the bleb remodeling. 
Conversely, the interventional approach can be minimal, via the use of topical injections of antimetabolites (5-
FU and MMC) and more recently anti-VEGF (bevacizumab), or more aggressive, with the revision of the 
trabeculectomy, a redo procedure or a glaucoma drainage device implantation. Furthermore when the choice 
falls on a revision the options are either to rescue the bleb with a needling procedure or to perform a more 
invasive full revision of the original site, which involves the opening of the conjunctiva and the dissection of the 
tissues. 
The bleb needling revision (BNR) is performed entering the conjunctiva far back from the filtering site and 
puncturing and cutting the fibrous tissue around the bleb with sweeping motion in the attempt of increasing 
the outflow. Traditionally three types of BNR are recognized: type 1 when is limited to the subconjunctival 
space, type 2 when the needle is used to break fibrous tissue under the scleral flap (often blindly identified by 
the consistence of the tissue encountered) and type 3 when the anterior chamber is fully entered.  The 
procedure is often associated with the use of antimetabolites to enhance the chances of success. Most of the 
times 0.1 ml of the pyrimidine analogue 5-fluorouracil (5-FU) is injected under the conjunctive surrounding the 
treatment area. However other techniques implement the antibiotic mitomycin C (MMC) usually applied prior 
to the procedure either on top of the conjunctiva via sponges or under the conjunctiva by means of the 
injection of a small amount of a low concentration of it. 
The main advantages of the BNR are that is a quick, repeatable procedure that requires a limited manipulation 
of the tissues. On the other hands there are some risks such as: bleeding (under the conjunctiva or in the 
anterior chamber), conjunctival buttonholes and leakage, hypotony, shallowing of the anterior chamber, 
corneal decompensation, damage to intraocular tissues, aqueous misdirection (malignant glaucoma), choroidal 
detachment and infection.  
The opinion on the efficacy of the BNR is still debated: some believe that should be avoided in the first place, as 
it jeopardizes the remaining function of the bleb and doesn’t offer any real advantage to the patient and the 
glaucoma specialist; others strongly advocate its use early on, even when the trabeculectomy activity seems 
adequate but the morphology of the bleb appears suboptimal. Moreover, when it comes to counsel a patient, 
the outcome of the procedure is difficult to predict and based on the results of previous studies and clinical 
experience, the chance of success is considered to be roughly 50 percent. 
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The aim of this study is to cast some light on the safety and efficacy of bleb needling revision performed on 
partly or completely failed trabeculectomies. In order to minimise the variables that could affect the reliability 
of the results we opted to include only the procedures carried out during a time window of 10 years (2004-
2014) in the same setting (Moorfields Eye Hospital, NHS Trust, London, UK) with a consistent technique. 
 
 
EPIDEMIOLOGY OF GLAUCOMA 
 
Glaucoma is considered the main cause of irreversible blindness worldwide. A recent epidemiological meta-
analysis was conducted in order to estimate the prevalence of glaucoma in 2013 and to project the number of 
people affected by 2020 and 2040.3 This was done using the World Population Prospects of the United Nations, 
which project the world population number based on population consensus and demographic surveys taking 
into account mortality and fertility rates. The pooled worldwide prevalence of glaucoma in the study was 3.54% 
with 95% credible intervals (CrIs) of 2.09-5.82%. Africa showed the highest prevalence of POAG with 4.20% 
(2.08-7.35) whereas Asia had the highest prevalence of primary angle closure glaucoma (PACG) with 1.26% 
(0.34-3.30). Europe showed the lowest global prevalence (2.93% [1.85-4.40]) among the macro-geographic 
continental regions considered (Asia, Africa, Europe, north America, Latin America and the Caribbean, and 
Oceania).  In terms of subtypes of glaucoma the prevalence of POAG was estimated at 2.51% (1.54-3.89) and 
the prevalence of PACG at 0.42% (0.13-0.98). Translated in to numbers it means that 6.77 million people were 
estimated to have glaucoma (both POAG and PACG) in Europe in 2013, with a prevalence of POAG 6 times 
higher than PACG. 
Furthermore the projections carried out showed a worldwide increase of prevalence from 64 million people in 
2013 to 76 million in 2020 and 111 million in 2040. This striking rise in the numbers is largely explained by the 
increase of life expectancy primarily in Asia and Africa with a consequent larger base of people at risk for 
glaucoma. From a European perspective, the number of people affected by glaucoma were estimated to be 
7.12 million by 2020 (5.67 with POAG and 1.46 with PACG respectively) and 7.85 by 2040 (6.39 with POAG and 
1.46 with PACG respectively) 
The results of the Bayesian multiple-adjusted meta-regression analysis are noteworthy. In fact they showed an 
higher odds ratio for POAG in men (OR: 1.36), people living in Africa (OR: 1.97), people living in urban areas (OR: 
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1.58) and people of African ancestry (OR: 2.80). The OR was 1.73 for each decade of age in the age interval 40-
80. Interestingly the age effect was found to be more pronounced in people of European and Hispanic ancestry 
compared to others. 
Among the epidemiological studies on glaucoma conducted in Italy, three of them seem of particular interest. 
The Egna-Neumarkt Study4 investigated the prevalence of ocular hypertension (OHT) and glaucoma in a 
population aged 40 or older in Alto Adige. The participation rate to the study was higher than 70% and the 
investigators found a 2.1% prevalence of OHT and a 1.4%, 0.6% and 0.6% prevalence of POAG, PACG and 
normal tension glaucomas (NTG) respectively.  
The Casteldaccia Eye Study5 found a 1.2% prevalence of chronic open angle glaucoma (presumably inclusive of 
POAG and NTG) and a 4.3% prevalence of OHT. The study was conducted in a small Sicilian town among people 
aged 40 or more and had a participation rate close to 70%. 
The Ponza Ophthalmological Survey6 included an analysis of prevalence of glaucoma among the population 
residing in Ponza Island. The survey achieved a participation rate higher than 80% and enrolled people aged 40 
or older. The results of the survey showed a 2.51% prevalence of POAG, a 0.97% prevalence of PACG and a 6.00% 
prevalence of OHT, with higher figures compared to the afore mentioned studies in terms of POAG and OHT. 
 
 
TRABECULECTOMY AND THE FIGHT AGAINST SCAR FORMATION 
 
When the glaucomatous optic neuropathy (GON) progresses despite the use of all the eyedrops that proved to 
be effective and tolerated by the patient (i.e. maximal tolerated medical treatment or MTMT) the next sensible 
options is the surgery in the majority of the cases. Trabeculectomy remains the most common option as a first 
surgical treatment for most of the glaucoma subtypes. The rationale of the procedure is to create a bypass 
through the scleral wall to allow the egress of aqueous humor in the extraocular space under the conjunctiva, 
where a small blister, commonly termed “bleb”, is formed. From that area the aqueous humor is reabsorbed by 
the blood and lymphatic vessels of the conjunctiva. Alternatively microscopic droplets of aqueous can work 
their way through the conjunctiva and join the tear film where they are drained by the lacrimal pathways. 
These tiny droplets are sometimes visible in forms of microcysts at the level of the filtering site during the 
clinical examination at the slit lamp; their presence is thought to be a sign of a functioning trabeculectomy. 
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Regardless of the extra care taken during surgery to fashion the filtering site, the human body is programmed 
to heal the wounds, and trabeculectomy makes no exception. The wound healing process is the major 
responsible for the impediment to achieve higher success rates. Known risk factors for scar formation are 
previous surgeries involving the conjunctiva, long use of preserved eyedrops, conjunctival inflammation (such 
as in belpharoconjuncitvitis, commonly seen in elderly), ethnicity (with greater risk in people of African 
ancestry) and young age. Therefore one of the most challenging part of the management of the surgical 
patients is the fight against scar formation which can impede the success of the procedure. It has been 
reported that despite the refinements of the surgical technique and the use of antinflammatory drugs and 
antimetabolites, still 35-43% of the patients don’t achieve a complete success, that is the maintenance of the 
target pressure without glaucoma drops.7-9 In the following paragraphs the main sources of failure of the 
trabeculectomy are briefly discussed. 
 
 
WOUND HEALING 
 
The wound repair response takes place in order to maintain the structural integrity of the tissues. On the other 
hand modulation of wound healing is deemed crucial in order to preserve the function of the filtering site. The 
healing process can be divided in three stages: the inflammatory phase, the proliferative phase and the 
remodeling phase. 
In the inflammatory phase the macrophages, recruited by means of increased tissue level of transforming 
growth factor beta (TGF-β), play a pivotal role creating the appropriate supply of cytokines (such as platelet 
derived growth factor [PDGF], fibroblast growth factor [FGF], epidermal growth factor [EGF] and TGF-β) and 
interacting with fibroblasts and T lymphocytes to coordinate tissue response.10 
Also T lymphocytes are considered essential to regulate the transition between the different stages of the 
healing response.  
In the proliferative phase the first event is the restoration of the epithelial integrity by means of migration of 
the surrounding cells and then by cell multiplication. Subsequently the granulation tissue forms, thank to two 
concomitant events: angiogenesis and fibroplasia. 
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Angiogenesis, promoted by the release of vascular endothelial growth factor (VEGF) and bFGF by platelets and 
macrophages, leads to the formation of new capillary beds through proliferation of vascular endothelial cells.11 
Fibroplasia, on the other hand, is induced by increased levels of PDGF and TGF-β  and consists in the 
proliferation of fibroblasts and the deposition of connective tissue in the site of injury.12 The fibroblasts migrate 
in the tissue through an appropriate balance between matrix metalloproteinases (MMPs) and tissue inhibitor 
metalloproteinases (TIMPs). The deposition of collagen is stimulated by the presence of TGF-β and interleukin-
4 (IL-4).13 
Tissue remodeling is the last phase of wound healing. It involves the transition to a different type of tissue 
through the differentiation of some of the fibroblasts in myofibroblasts and in fibrocytes and the change of the 
prevailing type of collagen (from type III to type I). The transition from fibroblast to the highly contractile 
phenotype typical of myofibroblast is promoted by TGF-β and is marked by the expression of alpha smooth-
muscle actin (α-SMA) and by increasing levels of extracellular matrix (ECM) proteins such as fibronectin, 
tenascins and collagens.14 In the fine balance between an excessive amount of scarring and the lack of 
appropriate wound repair, it seems that myofibroblast apoptosis plays a vital role. In fact, in a simplistic 
manner, scar formation may be considered as an overreaching wound healing process, characterized by a 
prolonged or enhanced myofibroblast stimulation. 
 
 
TRIGGERS FOR FIBROSIS FOLLOWING TRABECULECTOMY 
 
The conjunctiva may respond to a variety of stimuli modulating the healing process. A careful clinical 
examination and assessment of the past ocular history can highlight potential risk factors for an abnormal scar 
formation. The vast majority of the patients undergo a surgical treatment for glaucoma following many years of 
uninterrupted medical treatment. A good proportion of them may also show a certain degree of ocular surface 
disease (OSD) which may be exacerbated by the chronic exposure to some toxic preservatives and allergenic 
glaucoma drugs.15 Chronic inflammation leads to increased levels of IL-1 and TNF-α which promote fibrosis via a 
TGF-β mediated pathway.16-17 Also Th2 lymphocytes mediated allergic reactions, such as those caused by 
certain IOP lowering agents, may enhance fibrosis via an IL-13 mechanism.18 Previous studies have 
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demonstrated a beneficial effect of pretreatment with short courses of non-steroidal or steroidal 
antinflammatory drugs prior to trabeculectomy.19,20 
The conjunctiva may also be in an activated state following previous accidental traumas or surgical 
manipulations. As far as the inflammation is concerned the same principles hold true; however in these cases 
also the composition of the ECM play an important role. The ECM changes its phenotype and retains a certain 
amount of growth factors like VEGF-A, FGF and TGF-β which may be released and readily available following a 
surgical injury.21 Furthermore certain molecules, such as the ED-A splice variation of fibronectin,22 and some 
matricellular proteins, such as CTGF and SPARC, may act as enhancers of the scar formation.23,24 
Aqueous humor may have a detrimental role in the filtering function of the trabeculectomy. Some of the 
molecules contained in the aqueous of glaucoma patients, such as TGF-β, VEGF, PDGF, IL-8, serum amyloid A, 
TNF-α and plasminogen activated inhibitor (PAI-1) , exhibit a profibrotic activity.25-28 Along these lines lower 
levels of VEGF-A and TGF-β have been associated with more favorable outcomes of glaucoma surgery.25 
Together with the biochemical effect of the aqueous composition also the physical properties of the aqueous 
outflow may impact on the tissue response to the surgery. The characteristics of the flow (in terms of speed 
and direction), hydrostatic pressure, tissue permeability and absorption have been investigated and found to 
contribute to the scar formation process.29 Interestingly the sole interstitial flow of aqueous in the 
subconjunctival space is deemed to activate biochemical signals for fibrosis via mechanotransduction.30 
In an in vitro 3D cell culture model, slow interstitial fluid flow has proven sufficient to induce fibroblasts 
proliferation, TGF-β1-dependent myofibroblast transdifferentiation and ECM rearrangements.31 Furthermore 
experiments with cells in a 3D environment showed that ECM fibers orientation was perpendicular to the 
direction of the fluid flow in order to reduce the mechanical stress on the cells.32  This resulted in a lower 
permeability and higher hydrostatic pressure. All these observations need to be born in mind and further 
investigated in order to reach a better insight on their effect on the surgical outcome. 
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WOUND HEALING MODULATION: PRESENT AND FUTURE 
 
The inflammation preceding and following glaucoma surgery is typically targeted by the use of topical steroid 
drugs. In order to limit the scar formation the filtering site is treated intraoperatively with application of the 
antimetabolite mytomicin-C (MMC) at variable concentration depending on the risk profile.33 The drug  is an 
antibiotic derived from an actinobacterium, Strepotmyces caespitosus, and acts via a non-cell cycle-specific 
manner. It alkylates and cross-links DNA in target cells and therefore inhibits DNA synthesis with a cytostatic 
effect leading to cell apoptosis in Tenon’s fibroblast cell coltures. One common treatment protocol entails the 
application of 0.4 mg/ml MMC soaked sponges for 3 minutes intraoperatively on a broad area of episcleral 
tissue and under the scleral flap to prevent fibrosis and promote a posterior flow of the aqueous. Another 
common antimetabolite is 5-fluorouracil (5-FU) which is typically administered postoperatively via 
subconjunctival injection of 0.1-0.2 cc of 50 mg/ml solutions.34 The drug, which is commonly used also 
following trabeculectomy bleb needle revisions (BNR), is less potent compared to MMC as it targets DNA only 
in cells on S-phase.  
Despite the good results obtained with the state of the art treatment, an increasing amount of studies are 
exploring alternative solutions to achieve more consistent results. 
The inhibition of cyclin-dependent kinase (CDK) has shown preliminary good results in rabbit models of 
glaucoma surgery and seems to offer a viable approach to inhibit excessive fibrosis with a better safety profile 
compared to antimetabolites.35 
Previous phase III clinical trials, exploring the use of an isoform-specific TGF-β2 antibody, have failed to prove 
an important role of TGF-β2 inhibition in limiting fibrosis.7 That was unexpected considering the role of the 
molecule in the promotion of scarring and its increased concentration in the aqueous of glaucoma patients. 
However it is possible that a different scheme of administration or the use of an antibody targeting both 
isoforms of TGF-β may yield different results. Yet a safety issue may arise, as TGF-β is implicated in 
immunomodulatory and tumor-suppressive activities. 
The employment of anti-VEGF for glaucoma surgery is receiving increasing attention in the recent years. 
Although the use anti-VEGF alone is not superior to current antimetabolites, it seems that its combination with 
the actual treatment strategies permit to achieve better results.36 VEGF is responsible for increased vascular 
permeability and oedema, hence its inhibition lessen the availability of pro inflammatory and pro fibrotic 
molecules at the level of the filtering site. 
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Rho-kinase inhibitors are likely to enter the market of glaucoma eyedrops in the near future. However they 
may exhibit another interesting effect in reducing the cell contractility and therefore downregulate 
mechanotransduction.37 Statins inhibit Rho signaling by preventing its post-translational isoprenylation and 
showed similar effects on myofibroblast transdifferentiation as Rho-kinase inhibitors in vitro.38 
MicroRNAs (miRNAs) are non-coding RNA segments that are regulating protein expression patterns on a broad 
scale. There is mounting evidence linking decreased concentration of miR-29 to higher degree of fibrosis.39 On 
the other hand overexpression of miR-29 suppressed collagen-1 expression in human Tenon’s fibroblasts.40 
These observations pave the way for a potential role of miR-29 as an antiscarring agent in glaucoma surgery. 
 
 
RISK FOR FAILURE AND THE ROLE OF ANTIMETABOLITES 
 
The remodeling process of the filtering site following trabeculectomy doesn’t subside few months after surgery 
indeed it can continue for as long as 1 year before slowing down and reaching a quiescent phase. In order to 
achieve the desired wound modulation there are 4 critical points to consider. First the surgery must be 
performed with the least possible manipulation and trauma of the tissues, so that the inflammation response is 
minimized. Second, whenever possible, the conjunctiva should be spared from pro-inflammatory agents, such 
as benzalkonium chloride preserved drops and ideally treated with topical steroid to diminish the load of 
inflammatory cells. Third an antimetabolite augmented procedure, which consists in the use of agents such as 
MMC and 5-FU, should be employed, with a concentration and application time proportional to the predicted 
risk of failure. Lastly a trabeculectomy bleb needle revision, enhanced by the use of MMC or 5-FU, should be 
considered when, despite all the efforts, the bleb shows signs of imminent failure. 
Success rates of trabeculectomies may vary depending on many factors, among which are patient demographic 
characteristic, technique employed, use of antimetabolites, follow-up time and success criteria. In an elderly, 
low risk population, MMC-augmented trabeculecotmy achieved an IOP <18 mmHg in 73.1% of the eyes and IOP 
< 14 mmHg in 56.7% of the eyes at 9 years.41 More recently a retrospective study highlighted the satisfactory 
results obtained in 428 eyes of 395 patients who underwent trabeculectomy. Of these, 63% were performed 
with MMC, 30% with 5-FU and the rest without antimetabolites. At 2 year follow-up 87% of the eyes were 
achieved overall success according to the first criterion (IOP ≤21 mmHg and 20% IOP reduction from baseline) 
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and 86% were considered successful based on the second criterion (IOP ≤18 mmHg and 20% IOP reduction 
from baseline).2 Interestingly about 17% of the eyes required a 5-FU-augmented bleb needling revision; this 
underscores the important role of this procedure in the armamentarium of the glaucoma surgeon. 
5-FU is a pyrimidine analogue which prevents inclusion of thymidine in the DNA chains and interferes with RNA 
and ribosomal RNA synthesis. As a result it can effectively control the scar deposition and improve the outcome 
of trabeculectomy. Even though it has been used as a intraoperative antimetabolite, at present its use is largely 
prevalent in the postoperative time, for the treatment of failing bleb via subconjunctival injections. Another 
major role of 5-FU is in the antimetabolite-enhanced bleb needle revision procedures at the dose of 5-10 
mg/ml. Studies investigating the efficacy of 5-FU as the sole wound-healing modulator found improved 
outcomes compared to trabeculectomy without the use of antimetabolites. The success rates reported range 
from 77.8% at 5 years for low risk eyes (success criterion: IOP ≤21 mmHg),42 to 49% for high risk eyes.43 
Interestingly, in studies where 5-FU-augmented trabeculecotmies were compared head to head with those 
enhanced with MMC, the results were mostly non statistically different. 
It is widely accepted that some eyes have a less satisfactory outcome following trabeculectomy. Typical risk 
factors for anterior filtering surgery failure are: young age (less than 40 years old, although no clear cutoff has 
been established), black ethnicity, previous long exposure to preserved eyedrops, previous surgeries involving 
the conjunctiva, and certain seconday glaucomas (such as traumatic, neovascular, uveitic and ICE related). The 
mechanisms proposed to explain the higher failure rate in these eyes are different: they range from an 
increased number of conjunctival fibroblasts and inflammatory cells (macrophages, lymphocytes and mast-cells) 
to changes in the aqueous humor composition due to a blood aqueous barrier breakdown or an anatomical 
insult. These changes result in a primed conjunctiva which is more likely to exhibit an exaggerated healing 
response and therefore a lower chance to achieve the desired outcome.44 For this reason is extremely 
important to modulate the intraoperative and postoperative approach (particularly in terms of the use of 
antimetabolites) in order to prevent a potential early failure.  
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5-FLUOROURACIL (5-FU) 
 
5-Fluorouracil (5-FU) is a pyrimidine analogue with a chemical structure similar to thymine and uracil. It was 
first synthetized and described in 1957 by Dushinski et al45 and it was later found to have promising effect in 
the treatment of different types of tumors (head, neck, gastrointestinal tract and breast). 5-FU has several 
cytotoxic properties that make it useful in Ophthalmology: 1) its active metabolite, 5-fluorodeoxyuridine 5’-
monophosphate (FdUMP), inhibits thymidylate synthetase and the incorporation of thymidine in DNA (only in 
cells in S phase of the cell cycle); 2) it is incorporated in RNA and it interferes with the synthesis of RNA and 
ribosomal RNA; 3) it causes indirect disruption of the actin cytoskeleton in a dose-dependent way; 4) it 
promotes apoptosis of Tenon’s capsule fibroblasts.46 
The potential benefits offered by 5-FU have prompted its employment in different areas of ophthalmic surgery, 
ranging from glaucoma filtering surgery to pterygium, lacrimal surgery, proliferative vitreoretinopathy and 
ocular surface neoplasia. As far as glaucoma surgery is concerned, 5-FU has been investigated in primary 
trabeculectomy, combined cataract and glaucoma surgery, trabeculectomy bleb needling revision, pediatric 
glaucoma surgery and glaucoma drainage device implantation. In primary trabeculectomy studies have shown 
improved surgical outcomes both with repeated 5-FU subconjunctival injections postoperatively,47 and with 5-
FU soaked sponges application during the intraoperative time. Interestingly the outcomes of 5-FU augmented 
trabeculectomy were reported to be similar of those of MMC enhanced trabeculectomy.48,49 However the 
latter has replaced intraoperative 5-FU in the vast majorities of the cases, owing to a cell-cycle independent 
cytotoxic effect and the evidence of inhibiting effect on vascular endothelial cells highlighted in an animal 
experimental model.50 Trabeculectomy bleb needling revision is a procedure to revive failing or failed 
trabeculectomies; in these settings 5-FU is still the most common drug employed to improve the outcomes due 
to its favorable efficacy and safety profiles. The antifibrotic drug is typically administered at the end of the 
surgery via subconjunctival injections next to the area of the filtering bleb. 
In terms of complications, 5-FU is considered more forgiving than more potent antimetabolites such as MMC. 
However there are still concerns related to its effect on actively replicating cells such as corneal epithelial cells. 
Relatively common manifestations of corneal exposure to 5-FU include punctate keratopathy, filamentary 
keratopathy, and epithelial defects. These changes are usually reversible and self-limiting. However more 
serious events like bacterial ulceration, corneal melting and perforation have also been described. In order to 
limit the corneal exposure to 5-FU, a no-reflux injection technique is commonly adopted which consists in the 
use of cotton-tip applicator to tamponade the reflux of 5-FU from the needle entry site.51 
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 Another potential source of complications is the thinner and more avascular anatomy of the bleb achieved 
with the use of an antifibrotic agent. This can lead to bleb oozing, bleb or wound leaking and bleb related 
infections such as blebitis and bleb related endophthalmitis. Despite the fact that there is no way to have 
complete control on the amount of effect of antifibrotic agents on the ocular tissues, one interesting technique 
has been described to highlight tissue exposure to 5-FU or MMC. This technique is based on the use of trypan 
blue dyed 5-FU and MMC and has the advantage to easily demarcate the extent of the treated area and to 
pinpoint potential issues such as antimetabolite entry in the AC and reflux from the needle entry site. 
According to the authors of the study, the modified procedure showed that there is a direct correlation 
between the advancement of the needle under the conjunctiva and the tissue surface reached by the injected 
antimetabolite. Moreover the presence of subconjunctival fibrotic bands is delineated by the distribution of 
the dye, allowing for a more extensive breakage of scar tissue. This approach, provided its efficacy is 
demonstrated to be equal to the standard one, might help to minimize the rate of complications related to the 
use of antimetabolites.52 
 
 
BLEB NEEDLE REVISION TYPE: BLEB MORPHOLOGY AND THE LOCATION OF RESISTANCE 
 
Prior to undertake a bleb needle trabeculectomy revision, one must carefully assess the eye to be operated on 
in order to establish the best surgical approach. Once an obstruction of the ostium has been excluded via 
gonioscopy, other features of the bleb can be examined. In the attempt to facilitate the description of the bleb 
morphology several authors have developed grading systems, of which the most wide spread are the Indiana 
Bleb Appearance Grading Scale (IBAGS) and the Moorfields Bleb Grading System (MBGS).53 They both provide 
handy tools to classify the bleb morphology, although sometimes a bleb can present with a mixed morphology 
which make it difficult to allocate it to a specific subtype. 
 Depending on the site where the fibrosis process occurs, the location of resistance may vary and may 
therefore affect the morphology of the bleb. When the scar tissue surrounds the filtering bleb a so-called “ring 
of steel” forms and confers an “encapsulated” or “encysted” appearance to the bleb. This translates in a dome-
shaped, tense, elevated bleb which is translucent and filled by the trapped aqueous. In other circumstances the 
main site of resistance may be at the level of the scleral flap and the bleb is usually shallow or completely flat. 
A classification of needling has been proposed to indicate where the procedure takes place: type I needling is 
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performed over the sclera at the level of Tenon’s or subconjunctival tissue (this is primarily useful in the 
management of encapsulated blebs); type II needling extends the sweeping motion of the needle tip to the 
edge of the scleral flap in order to release a fibrotic seal around it; finally type III needling advances under the 
scleral flap and through the sclerostomy in the anterior chamber and reforms the whole outflow pathway.54 It 
is straightforward that the latter type is more likely to cause early hypotony for the complete absence of 
resistance which may follow its execution.  
It has to be born in mind that just as one’s ability to assess the function of a trabeculectomy by the bleb 
morphology is limited, so is the ability to determine the location of outflow resistance by the sole clinical 
inspection of the bleb (with the notable exception of Tenon’s cysts). 
 
 
BLEB NEEDLE REVISION (BNR): WHEN TO CONSIDER IT AND WHEN TO AVOID IT 
 
The main and most common reason to offer a bleb needling revision to a patient is undoubtedly the presence 
of a failing or failed trabeculectomy bleb. When it comes to classify a bleb as “amenable” to needling there is 
still no strict consensus among different glaucoma specialists. Some textbooks and peer-reviewed papers 
consider bleb needling revision a surgical approach applicable only when dealing with encapsulated blebs (also 
known as Tenon’s cysts). These typically form in the early period after trabeculectomy or phacoemulsification 
(in eyes which previously underwent trabeculectomy) due to the deposition of scar tissue around the filtering 
area resulting in a dome-shaped, elevated, vascularized and tense bleb. Others have described the outcome of 
this procedure on blebs with a great variety of morphologies, ranging from dome-shaped encapsulated blebs to 
flat and scarred blebs.  
However there are other instances when bleb needling revision could prove useful. For example, in the 
presence of a bleb with a markedly elevated profile which is associated with bleb dysesthesia, the revision may 
help to achieve a more diffuse, flatter morphology with a resulting improvement in the ocular comfort and 
possibly the resolution of the symptoms.  
Also thin-walled, avascular, cystic blebs may be considered as appropriate targets for bleb needling revision. It 
has been shown that these types of blebs are associated with an increased risk of bleb related infections (BRI), 
such as blebitis and bleb-related endophthalmitis (BRE).55 While the former is confined to the external ocular 
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tissues and can have satisfactory outcomes when promptly recognized and treated, the latter involves the 
intraocular space and can lead to devastating consequences to the structural and functional integrity of the 
eye .  
Bleb needling revision relies on the breakage of scar tissue via sweeping movements of a fine needle tip;  in the 
traditional technique there are no flow restrictors and the success of the procedure depends on a fine balance 
between the removal of resistance and the presence of residual fibrotic tissue to prevent a crash of the IOP. 
Therefore there are circumstances where a bleb needling revision might be contraindicated for the increased 
risks of persistent hypotony and hypotony-related complications (i.e. flat anterior chamber, choroidal 
detachment, suprachoroidal hemorrhage, hypotony maculopathy and pseudo-papilloedema ex-vacuo). 
Patients with a potentially impaired ciliary body function, such as those with a history of chronic uveitis and 
diabetes mellitus or those who underwent previous ciliary body ablation procedures, present with an higher 
risk of these complications. The same holds true in patients who are traditionally at greater risk of hypotony 
following trabeculectomy, such as high myopes. In those cases different approaches, such as a same site 
extensive trabeculectomy revision, a redo trabeculectomy or a glaucoma drainage device insertion. 
 
 
BLEB NEEDLE REVISION (BNR): TECHNIQUES 
 
The procedure can be performed at the slit-lamp or in a more controlled environment such as the operating 
theatre. The preparation of the eye is similar to other surgeries, with the use of a drape to isolate the eye, a lid 
speculum to maintain the proper exposure of the tissues, and povidone iodine 5% eyedrops as disinfectant.  
In terms of antifibrotic agents the choice is between mitomycin-C (MMC) or 5-fluorouracil (5-FU). A small 
amount of the former (0.1 ml) can be injected under the conjunctiva immediately before the procedure in a 
concentration which may vary from 0.2 mg/ml to 0.5mg/ml, depending on the risk factors for recurrence of 
failure. Alternatively MMC con be applied on top of the conjunctiva pre or post-operatively via soaked sponges 
for a variable period of time (generally no longer than 6 minutes). However 5-FU is still the most common 
antifibrotic agent employed after needling, partly because is less potent and therefore considered safer to 
inject. Also there are concerns related the overdose of MMC to which ocular tissues are exposed, with 
potential long term side effects such as scleral thinning and ciliary body shutdown. For these reasons some 
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clinicians are reluctant to “poison” the eye with repeated exposure to MMC. 5-FU is injected next to the bleb 
area, rather than into the bleb, in a concentration usually between 5 to 10 mg (0.1 to 0.2 ml of 50mg/ml 
formulation). 
The sharp instrument used to puncture and break the fibrotic septa which separate the loculations within the 
bleb may also vary depending of the type of bleb and on the preference of the operator. A 30 gauge fine 
needle has the advantage of producing a tiny self-sealing conjunctival entry site but is less effective when trying 
to disassemble thick fibrotic bands. On the other hand a 23 gauge microvitreoretinal (MVR) blade ensures a 
greater cutting ability but requires a proper closure of the entry hole with a suture or diathermy. An 
intermediate solution is the use of a 25 gauge (orange) needle, which has some of the advantages of both the 
aforementioned instruments.  The entry site should be at least 10 mm from the main loculation of the bleb 
which sit above the scleral flap. Ideally the bleb margins should be approached either form the temporal or the 
superior side, to promote the extension of the filtering area in those directions. The nasal side should be 
avoided if possible, since an overdraining bleb on that side has higher chances to cause dysesthesia. 
One of the main limitations of BNR is the lack of a fine control over the amount of flow restored. The aim of the 
procedure is essentially to defy the outflow resistance which, depending on the bleb morphology, may be 
predominantly at the level of the scleral flap or at the level of the subconjunctival space. The needle employed 
for the procedure allows to reduce the risks of a significant bleb leakage and doesn’t require to place a suture 
at the end of the maneuver. On the other hand there is no direct exposure of the subconjunctival tissues and 
every step is performed either looking carefully through the conjunctiva or, when the visibility is suboptimal or 
completely absent, relying only on the tactile feedback of the tissues. This can lead to an insufficient disruption 
of the scar tissue and a subsequent insignificant reduction of IOP or conversely to an extensive loss of the 
tissue resistance followed by a massive drop of the IOP. These observations have prompted surgeons to 
implement some modifications of the original technique to try and achieve a better control on the outcome. 
Laspas et al56 recently described a restrospective interventional case series of two groups of patients with 
failed trabeculectomies: the first group (23 eyes of 23 patients) underwent a typical needling procedure 
whereas the other group (23 eyes of 23 patients) was treated with a combination of needling and  
transconjunctival scleral flap sutures. The authors found that the percentage of hypotony and the percentage 
of complications related to hypotony (such as choroidal effusion) was 5 fold higher and 2 fold higher 
respectively in the sole needling group. Although the limited number of patients considered in the paper 
prevented any definite conclusions, the authors suggest that the use of transconjunctival scleral flap sutures in 
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patients with high risk profile for hypotony might be able to preempt a significant proportion of hypotony 
related complications. 
Wilson et al57 described a restrospective case series of 33 eyes of 30 patients who underwent a modified bleb 
needle technique. The main difference compared with the standard approach was the use of an anterior 
chamber maintainer. An advantage of that modification was that continuous infusion of BSS into the anterior 
chamber throughout the needling procedure allowed to receive an immediate feedback regarding the recovery 
of the drainage and to avoid an overtreatment with the risk of hypotony. The study compared favorably with 
previous similar ones: survival analysis showed an overall success in 64% of the patients at 12 months. Mean 
IOP at last follow-up was 14.3±2.8 mmHg, significantly lower than the baseline pre-treatment IOP  of 22.1±9.24 
mmHg (p <0.05). 
Dada et al58 have applied advanced technologies like intraoperative OCT to the needling procedure in order to 
get a visualization of the scar tissue and to maneuver the needle more effectively at the level of the 
subconjunctival space and under the scleral flap until the anterior chamber.  
 
 
BLEB NEEDLE REVISION (BNR): COMPLICATIONS 
 
The entire spectrum of complications which may arise following a trabeculectomy may develop after a bleb 
needling revision. The most common complications are 5-FU related corneal epithelium toxicity and 
subconjunctival haemorrhage in the area of the bleb. The latter may increase the risk of failure of the 
procedure due to the incitement of scar tissue deposition. Other relatively infrequent complications are 
anterior uveitis, hyphema, shallowing of the anterior chamber, hypotony, serous choroidal detachment and 
hypotony maculopathy. More serious complications such as aqueous misdirection syndrome, loss of sight and 
bleb related infections are rare but also possible and should be recognized and treated promptly.  
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STUDY INTRODUCTION 
 
Trabeculectomy still represents the first choice in the management of many types of glaucomas. Despite the 
improvement of the efficacy and safety of the procedure achieved over many years of refinement of the 
technique (including the introduction of antimetabolite) there is still a significant percentage of patients who 
fail to accomplish the desired target IOP. These patients may show signs of failure in the early postoperative 
time or less commonly many years after surgery. Subconjunctival injections of steroids or 5-FU, removal or 
adjustment of releasable sutures, laser suture lysis and self-massage of the eyeball may prove effective in 
reviving the bleb in the first month following the surgery, and sometimes even longer than that. However after 
all these steps have been attempted or when the bleb function deteriorates many months or years after 
surgery, the surgeon is faced with the decision of what to do next. One option is to “accept” the failure of the 
trabeculectomy and move forward to another treatment modality: IOP lowering eyedrops, trabeculectomy 
same-site revision, redo trabeculectomy, minimally invasive glaucoma surgery (so called MIGS, usually 
performed combined with phacoemulsification in phakic eyes), glaucoma drainage device (GDD) implantation 
or ciliary body ablation procedures. Another approach is to “refuse” the failure of the trabeculectomy and to 
try and rescue it performing one or more bleb needle revisions (BNRs). There is still controversy around the 
safety and efficacy of BNR. The scope of this study is to highlight the performance of this procedure in a large 
number of patients in a single centre, employing a consistent surgical technique to minimise the surgical-
related confounding factors. 
 
 
PATIENTS AND METHODS 
 
Patients who underwent trabeculectomy bleb needle revision (BNR) with a consistent technique over 10 years 
(2004-2014) were retrospectively reviewed in a single centre (Moorfields Eye Hospital, NHS Trust, London, UK). 
Two-hundred and thirteen eyes of 212 patients were identified. Nine patients were excluded because the 
needling was performed with a technique not consistent with the others, 1 patient was removed from the list 
because needling was cancelled and 10 patients were excluded from the study for the lack of data on the 
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procedures. This led to a total number of 192 eyes of 192 patients. All the patients had at least one BNR done, 
whereas 52 eyes of 52 patients underwent two or more revision procedures. 
The procedures were all performed in the theatre by different surgeons but following a consistent technique. 
After administration of a topical anesthetic (tetracaine hydrochloride 1%) and topical povidone iodine 5%, each 
eye was draped and an eye speculum was placed. A drop of vasoconstrictor (phenylephrine 2.5%) was instilled 
whenever the conjunctiva was deemed to be too hyperemic  and therefore at greater risk of bleeding. An 
insulin syringe with a 30 gauge needle attached to it or a 25 gauge orange needle mounted on a tuberculin 
syringe were bent at the junction with the syringe and used for the needling (Figure 1). The conjunctiva was 
entered far superiorly towards the fornix with the help of a forceps. The bevel-up needle was then directed 
tangential to the episcleral surface and towards the bleb area until resistance was appreciated at the tip of the 
needle. The sharp tip and the cutting edges of the needle were then used to puncture and disrupt the fibrotic 
bands approached by means of back and forth and sweeping movements (type 1 needling). The endpoint of 
the procedure was an elevation of the bleb which corresponded to a softening of the eyeball. In cases where 
the outflow was deemed inadequate, the needle was advanced at the edges and under the scleral flap (type 2 
needling) and if still not sufficient into the anterior chamber (type 3 needling). When the procedure was 
completed the needle was withdrawn and an injection of 0.1 to 0.2 ml of 5-FU (50 mg/ml) was delivered 
followed by one of 0.1 ml of steroid (dexamethasone or betamethasone).  
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Figure 1 - Bleb needling revision (BNR). A) needle entering subconjunctival space; B) fibrotic adhesions disrupted by sweeping motion; 
C) subconjunctival bleed; D) injection of 5-FU. 
 
Each patient was instructed to instill steroid drops (dexamethasone 0.1%) 2 hourly until review and antibiotic 
drops (chloramphenicol 0.5%) four times a day for two weeks. The topical steroid drops were tapered down 
according to the appearance of the bleb following the procedure. Additional 5-FU or steroid subconjunctival 
injections were administered in case of early signs of failure were spotted. The needling was repeated in 
patients in case of failures whenever the surgeon felt that a repeat procedure could have proved successful. 
Three criteria for defining success were identified based on IOP reduction only: A) IOP equal or less than 21 
mmHg and at least 20% reduction from baseline IOP; B) IOP equal or less than 18 mmHg and at least 25% 
reduction from baseline IOP; C) IOP equal or less than 15 mmHg and at least 30% reduction from baseline IOP. 
Potential risk factors for failure considered were age, ethnicity, lens status, interval between trabeculectomy 
and needle revision, pre-needling IOP and early post-needling IOP. 
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STATISTICAL ANALYSIS 
 
Survival analysis with Kaplan-Meier curves was employed to investigate the probability of cumulative success 
based on the aforementioned three criteria. For the purposes of Kaplan-Meier plots, failure was defined as the 
occurrence of an IOP higher than the threshold set by the relevant criterion on two successive visits. If the IOP 
was above the threshold at the last follow-up visit, that was considered a failure as well. 
Cox proportional hazard regression analysis was carried out to highlight the association between study factors 
and time to IOP failure. Student paired t-test was used to compare pre-needling and post-needling IOP and 
Wilcoxon singed-rank test to assess number of eyedrops before and after bleb needle revision. 
The statistical analysis was conducted using R software (R software; provided in the public domain by the R 
Foundation for Statistical Computing, Vienna, Austria; available at www.r-project.org). A p value <0.05  was 
considered statistically significant. 
 
 
RESULTS 
 
One hundred ninety-three eyes of 171 patients who underwent bleb needle revision were included in the study. 
The demographic and surgical data of the patients are summarised in Table 1. The mean age±standard 
deviation (SD) of the patients was 71.4±13.9 (range, 25-97 years). The median interval between the index 
filtration surgery (trabeculectomy) and the bleb needle revision was 27.5 months with a range of 21 days to 
29,9 years. Median post-needling follow-up was 1.5 years (range 0-9 years). The patients were on a median of 
2 IOP lowering agents (range 0-4); 32% of them were off glaucoma eyedrop prior to the bleb needle revision.  
The mean pressure at baseline was 23.4 [±6.7 SD] mmHg with a range of 8 to 47 mmHg. After the revision the 
IOP decreased to 14.5 [±4.8 SD] mmHg at 1 year (range 4-31 mmHg), 13.09 [±4.0 SD] mmHg at 3 years (range 3-
26 mmHg), and 15.3 [±6.0 SD] mmHg at 5 year follow-up (range 7-38 mmHg). The comparison between 
preoperative and postoperative IOP at different follow-up intervals is illustrated in Figures 2-5. 
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Patients / Eyes, n 171 / 193 
Age, mean (SD) 71.4 (13.9) 
Gender, n (F:M) 79 : 92 
Eye, n (R:L) 100 : 93 
Ethnicity 
White, n (%) 80 (46.8) 
Black, n (%) 64 (37.4) 
Asians, n (%) 21 (12.2) 
Other, n (%) 6 (3.6) 
Type of glaucoma 
POAG, n (%) 137 (70.9) 
PACG, n (%) 14 (7.2) 
Secondary glaucomas, n (%) 42 (21.9) 
Lens Status 
Phakic, n (%) 103 (53.4) 
Pseudophakic, n (%) 84 (45.6) 
Missing data, n (%) 2 (1.0) 
Ocular Biometry 
Axial length (mm), mean (SD) 23.8 (2.7) 
Surgical data 
Antimetabolites during trabeculectomy, n (%) 157 (81.3) 
Interval between trabeculectomy and bleb needle revision 
(days), mean (SD) 
1967.8 (2349.9) 
Type of needling 
Type 1, n (%) 65 (33.7) 
Type 2, n (%) 43 (22.3) 
Type 3, n (%) 52 (26.9) 
Unknown, n (%) 33 (17.1) 
 
Table 1 - Demographic and surgical characteristic of the cohort of patients. 
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Figures 2-5 – Scatterplots showing baseline IOP against IOP at various follow-up 
points. Circles under the line of equity represent patients with lower IOP at 
follow-up. 
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Table 2 shows the IOP at baseline and at various follow-up points, together with a paired t-test to show the 
statistical significance of the IOP reduction after the procedure. Figure 6 shows a boxplot of the IOP against the 
follow-up time. 
 
IOP mmHg (SD) P value 
Baseline 23.4 (6.7) - 
1 Year 14.5 (4.8) <0.001 
2 Years 14.5 (5.1) <0.001 
3 Years 13.0 (4.0) <0.001 
4 Years 13.7 (4.5) <0.001 
5 Years 15.3 (6.0) <0.001 
6 Years 13.7 (4.2) <0.001 
7 Years 15.4 (5.7) 0.07 
8 Years 14.1 (2.4) 0.04 
 
Table 2 - IOP at baseline and at the various follow-up points with significance value. 
 
Figure 6 - Boxplot showing the IOP at various follow-up points with outliers. 
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The number of drops, indicated as individual agent, before and after the procedure is summarised in Table 4. 
 
n. agents P value 
Baseline 1.5 (1.3) - 
1 Year 0.8 (1.1) <0.001 
2 Years 1.3 (1.3) 0.14 
3 Years 1.3 (1.4) 0.07 
4 Years 1.2 (1.3) 0.05 
5 Years 1.5 (1.5) 0.65 
6 Years 1.5 (1.4) 0.51 
7 Years 1.6 (1.4) 0.20 
8 Years 2.3 (1.3) 0.77 
 
Table 3 - Number of agents at baseline and at varous follow-up points with significance value. 
 
Figure 7 – Boxlpot showing number of agents at various follow-up points. 
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The result of the survival analysis showed a probability of cumulative success at 1 year postoperatively of 63.0% 
[95% C.I. 55.4-69.7%], 51.1% [95% C.I. 43.5-58.2%] and 36.2% [95% C.I. 29.1-43.3%] according to criterion A, B 
and C respectively. The same analysis at 4 year follow-up showed the following figures: 49.8% [95% C.I. 41.0-
57.9%], 29.6% [95% C.I. 21.7-37.8%] and 20.7% [95% C.I. 14.2-27.8%]. The Kaplan-Meier survival analysis is 
depicted in Figure 8. 
 
Figure 8 – Kaplan Meier plot illustrating survival probabilities according to the three criteria 
 
The result of the Cox proportional hazards regression model showed the an immediate post needling IOP 
higher than 12 mmHg is associated with increased risk for failure for criterion B (HR=1.97 [95% C.I 1.17-3.33], 
p=0.010) and C (HR=1.81 [95% C.I 1.12-2.90], p=0.013) but not for criterion A. The relevant survival plots for 
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criterion B and C are shown in Figures 9 and 10. The log rank test was statistically significant for both plots 
(p=0.005 and p=0.014). The other predictors considered didn’t reach statistical significance in the analysis. 
 
Figure 9 – Kaplan Meier plot showing survival probabilities according to criterion B considering the dichotomous 
variable immediate IOP after BNR  >12 mmHg. 
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Figure 10 – Kaplan Meier plot showing survival probabilities according to criterion C considering the dichotomous 
variable immediate IOP after BNR  >12 mmHg. 
 
The complications which occurred as a consequence of bleb needling revision are listed in Table 4 (early 
postoperative time) and Table 5 (late postoperative time). Two patients lost 2 or more lines of vision at the last 
follow-up. One of them had hypotony and choroidal effusion which settled spontaneously, the other didn’t 
experience any complication and the loss of vision was probably associated with a worsening of the glaucoma, 
the development of cataract or both these conditions. 
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Early postoperative complication Number (%) 
Subconjunctival haemorrhage 33 (17%) 
Transient Hyphema 8 (4%) 
Hypotony (IOP <6 mmHg) 9 (4.7%) 
Serous choroidal detachment 2 (1%) 
Shallow anterior chamber 5 (2.6%) 
Other:  corneal damage 
 
high IOP (> 30 mmHg) 
bleed around iridectomy 
3 (1.5%) :1 patient with punctate epithelial erosion, 1 
with a corneal abrasion, and 1 with Descemet folds 
2 (1%) 
1 (0.5%) 
 
Table 4 –Early postoperative complications (within 3 months) following bleb needle revision. 
 
Late postoperative complication Number (%) 
Late bleb leak 2 (1%) 
Vitreous haemorrhage 2 (1%) 
Acute anterior uveitis 3 (1.5%) 
Chronic hypotony with hypotony maculopathy 1 (0.5%) 
Wipe out 1 (20.5%) 
Loss of ≥2 lines of vision (logMAR) 2 (1%) 
 
Table 5 – Late postoperative complications (later than 3 months) following bleb needle revision. 
 
 
DISCUSSION 
 
Trabeculectomy is still the mainstay of glaucoma surgeries and the first line surgical treatment in the majority 
of glaucoma subtypes. Despite the fact the surgery proves successful in a remarkable number of cases, the 
failure rate is not negligible. In a recent retrospective multicentre study2 assessing the IOP lowering 
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performance of trabeculectomy across different sites found that 13% of the patients failed to achieve the 
target IOP of ≤21 mmHg and a 20% reduction from baseline at 2 year follow-up despite the additional use of 
glaucoma eyedrops. Similarly 14% of the patients were classified of failure based on an IOP target of ≤18 
mmHg and a 25% reduction from baseline at 2 years in spite of IOP lowering topical medications. For those 
patients there is a need for an additional intervention aimed to achieve a more suitable IOP. In this respect it 
would be ideal to resort to an intervention which would enhance the function of the existing trabeculectomy 
filter. That intervention should allow to achieve a more suitable IOP and to postpone to a later stage more 
invasive procedures. Bleb needle revision (BNR) of trabeculectomy is an ideal candidate for that purpose. 
Hence an increased awareness on the outcome of bleb needle revision is desirable, so that the clinician can 
then make his mindful choice based on the available scientific evidence and the overall clinical picture. A 
decisional algorithm could be implemented in which, after a failed trabeculectomy, further available options 
are considered on the base of their impact on the conjunctiva. In that respect, one would prefer to attempt a 
bleb needle revision prior to resort to more invasive procedures such as a redo trabeculectomy or a glaucoma 
drainage device insertion. The minimal invasive nature of bleb needle revision allows to spare the conjunctiva 
and ideally to minimise tissue disturbance and therefore to recruit less inflammatory cells and fibroblasts. The 
augmentation of the procedure with the antimetabolite 5-flurouracil is meant to further keep the tissues as 
quiescent as possible. 
Broadway et al reported outcome data on bleb needle revision in one of the largest prospective studies on this 
subject, including 101 eyes of 101 patients.59 Almost a quarter of their patients had previous combined 
surgeries (cataract extraction and trabeculectomy), while the remaining had trabeculectomy alone. Fifty-seven 
eyes (56.4%) received an antifibrotic treatment perioperatively which consisted of 5-FU (44.5%), MMC (7.9%) 
or β-irradiation (4.0%). The authors describe success rates based on two criteria: IOP <22 mmHg with less 
glaucoma medications (criterion 1) or more than 30% reduction from baseline IOP and less glaucoma 
medications (criterion 2). Kaplan-Meier analysis showed a survival rate of 75% and 56% at 1 year according to 
criterion 1 and 2 respectively.  The outcomes of bleb needle revision in the study by Broadway et al seem 
better compared to the ones reported in this study (probability of survival of 63% at 1 year and 49.8% at 4 year 
according to criterion A, i.e. IOP ≤21 mmHg regardless of glaucoma eyedrops). However there are some 
differences between the studies which may have played a role in the dissimilar results. Broadway et al 
conducted a prospective study investigating the outcome of standardized bleb needling revision in eyes with 
failing or failed trabeculectomies. Thirty-three out of 101 eyes had redo needling done. Seventy-nine percent 
of the patients were Caucasian, 14% Afro-Caribbean and 7% Asian. Contrary to that the present study has a 
retrospective design and is focused on the outcome of single bleb needle revision. Fourty-seven percent of the 
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patients were Caucasian, 37% were African or Afro-Caribbean and 12% were Asian (4% were coded as other 
ethnicities). The disparity in the design (prospective vs retrospective), the number of procedures per eye 
(multiple vs single), the percentage of pseudophakic eyes (16% vs 46%) and the different proportions of 
ethnicities may account at least partly for the outcomes achieved in the studies. In the Cox proportional 
hazards regression analysis this study found immediate post BNR IOP >12 mmHg as a risk factor for failure, but 
only for the more stringent criteria B and C. In the paper by Broadway et al a lower pre-needling IOP is 
associated with success for criterion 1 (IOP <22 mmHg), whereas the opposite is true for criterion 2 (IOP <30%). 
The authors highlight that an IOP lower than 11 mmHg immediately after the procedure reached a statistical 
significance as indicator of success according to criterion 1. Other factors known to be associated with 
increased risk of failure (young age, non-white ethnicity, previous cataract surgery and shorter interval 
between index surgery and needling) were not found to affect the outcome. 
Rotchford et al reported the results of 5-FU augmented bleb needle revision in a prospective study involving a 
cohort of 81 patients.60 Fourty-six percent of them received an antimetabolite treatment (either 5-FU or MMC) 
at the time of the trabeculectomy and 12% had a combined phaco-trabeculectomy. The authors defined two 
criteria for success: IOP ≤21 mmHg and 20% pressure reduction from baseline with the same number of 
eyedrops or less; IOP ≤16 mmHg and 20% pressure reduction from baseline with the same number of eyedrops 
or less. The survival rates at 1 year were 54.3% and 53.1% according to criterion 1 and 2 respectively. At 3 years 
the survival analysis showed a probability of success of 31.9% and at 4 years of 13% with no difference 
between the two criteria. Similarly to what observed by Broadway et al59, the authors found that an IOP ≤10 
mmHg immediately after the procedure is an indicator of success. Patients that required more than one 
needling had a worse outcome compared to those who underwent a single procedure. Interestingly when the 
survival rate of the subgroup of patients with a single needling procedure was analysed, the success at 2 years 
was 59%, compared to 54% found in this study. Once again the slight disparity of results may be attributed to  
some baseline characteristics, such as the higher proportion of patients who were pseuodphakic and of black 
ethnicity in this study. 
In a large retrospective study analyzing the outcome of 5-FU augmented bleb needling revision on a cohort of 
175 Asian eyes, Tsai et al report the success rates of the two subgroups of POAG eyes (69%) and PACG eyes 
(31%).61 The definition of success was an IOP ≤21 mmHg and ≥6 mmHg. The success rates at 1 year was 89.5% 
and 87.5% at 1 year and 84.3% and 82.5% at 2 years for the POAG and PACG groups respectively. The log rank 
test showed no difference for the two subgroups in terms of survival probability. The survival rates in the paper 
by Tsai et al are particularly high compared to previous similar publications and to the present study. This may 
be related to the definition of success adopted by Tsai et al and to the fact that all the trabeculectomies were 
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augmented with MMC. The authors found that an higher IOP prior to the needling revision and the need for 
multiple procedures were predictors of failure.  
The results of this study and illustrates that bleb needle revision is a viable option to successfully resurrect a 
considerable number of failed trabeculectomies. Same-site trabeculectomy represents an alternative approach 
of revision that entails a more invasive procedure. It is essentially a trabeculetomy performed following the 
previously dissected tissues. Hirunpatravong et al published the results of same-site trabeculectomy revision 
with adjunctive MMC in a retrospective study including 130 eyes of 117 patients.62 The authors defined three 
levels of qualified success  (with and without drops) based on the following criteria: IOP ≤18 mmHg and 20% 
reduction from baseline; IOP ≤15 mmHg and 25% reduction from baseline and IOP ≤12 mmHg and 30% 
reduction from baseline. In case where both the baseline IOP and the postoperative IOP were equal or lower 
than the set cut-off, a reduction of 2 or more meds was considered a success regardless of the percentage of 
reduction. The survival probabilities at 1, 3 and 5 years were 69.7%, 58.2% and 51.5% for the first criterion; 
60.9%, 47.8% and 44.0% for the second criterion and 44.6%, 29.7% and 25.8% for the last criterion. Worse 
visual acuity at baseline and an interval from index surgery to revision of less than 3 years were found to be risk 
factors for all the criteria. The authors conclude that same-site trabeculectomy revision should be considered 
as a viable alternative to redo trabeculectomy (on a different site), particularly if the target IOP is in the mid or 
high teens. In comparison the survival rates in this study at 1,3 and 5 years were 51.1%, 39.0% and 27.7% for 
criterion B and 36.2%, 25.2% and 13.8% for criterion C. It is intuitive that a procedure such as same-site 
trabeculectomy revision, which involves the opening of the conjunctiva, the dissection of tissue and the 
application of the potent antimetabolite MMC, permits to achieve betters results in terms of IOP reduction and 
survival rates. However this is at the cost of a longer, more invasive and potentially more prone to complication 
procedure. 
In conclusion this study suggests that bleb needle revision is a safe and effective procedure which allows to 
rescue the trabeculectomy bleb function in a remarkable proportion of patients. It has the advantage of being 
quick and less invasive than other procedures. On the other hand the results of this study highlight that bleb 
needle revision proves to be more effective when the defined target IOP lies between the mid and the high 
teens. The presence of a significant lower mean IOP at the last follow-up point with a number of agents not 
significantly different from baseline suggests that this procedure is more effective at lowering IOP than at 
reducing the number of agents needed to control glaucoma progression. 
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Finally this study has limitations related to its retrospective design and potential selection bias. However the 
inclusion of procedures performed with a consistent technique hopefully minimized the variables related to the 
surgery. 
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